In silico screening of existing drugs reveals three candidates against SARS-CoV-2
2021
Drexel University, Philadelphia, USA
In this study, the researchers present a novel strategy for in silico molecular modelling, screening for potential drugs that may interact with multiple main proteins of SARS‐CoV‐2. Targeting multiple viral proteins is a novel drug discovery concept in that it enables the potential drugs to act on different stages of the virus’ life cycle, thereby potentially maximizing the drug potency. The authors screened 2631 US Food and Drug Administration (FDA)‐approved small molecules against 4 key proteins of SARS‐CoV‐2 that are known as attractive targets for antiviral drug development. In total, 29 drugs that could actively interact with 2 or more target proteins were identified, with 5 drugs being common candidates for all 4 key host proteins and 3 of them possessing the desirable molecular properties.
Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2
Hualou Liang
Added on: 05-11-2021
[1] https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.13007[2] https://www.drugtargetreview.com/news/84683/in-silico-screening-of-existing-drugs-reveals-three-candidates-against-sars-cov-2/?utm_source=Email+marketing&utm_medium=email&utm_campaign=DTR+-+Industry+Insight+-+Merck+-+Screening+-+30.04.21&utm_term=Dilyana%2c+learn+more+about+screening+in+drug+discovery&utm_content=https%3a%2f%2femails.drugtargetreview.com%2frussellpublishinglz%2f&gator_td=K2qyNB5MYk%2fx1C0MoQBLqMEirEZC6rQY69N%2fOA9dl6hblShBwaXogQWaQyqRmMFtg0BeRtE7AZ%2fFkNO3IEpkjFH%2fk8e8qxlK%2f9hi6wU8bB8K6EAsDCqxGJNWP2QUEWOIQb3nMvdj%2bb9jnhqFRLwGpRl3ie6Wa8mdOj0o1OiRSw%2fqK0vLtnmvOFqv5tILHp3Rrx%2bBlVfh2y6cszaPUzVGg8nZvsYh82x4dYs1g536By%2f9uvKTPly42cBu8%2fUKA%2bLh
